Altre lingue Windtree Therapeutics, Inc.

Azioni

WINT

US97382D5014

Mercato chiuso - Nasdaq Altri mercati azionari 22:30:00 25/04/2024			Variaz. 5gg	Var. 1 gen.
5,07 ^USD	-1,65%		-17,11%	-60,82%

16/04	Windtree Therapeutics, Inc. riporta i risultati degli utili per l'intero anno terminato il 31 dicembre 2023	CI
10/04	Transcript : Windtree Therapeutics, Inc. - Shareholder/Analyst Call

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Windtree Therapeutics : April'24 Corporate Presentation	24/04
Windtree Therapeutics Announces Reverse Stock Split	18/04
Windtree Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Key Business Updates	17/04
Windtree Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	16/04
North American Morning Briefing : Stock Futures -2-	11/04
Windtree Therapeutics to Acquire Cancer Treatment From Varian Biopharmaceuticals	09/04
Windtree Acquires Early-Stage, Novel Oncology Platform and Completes $1.5 Million Convertible Note Bridge Financing	08/04
Windtree Therapeutics, Inc. announced that it has received $1.5 million in funding	08/04
Windtree Therapeutics, Inc. acquired All of the assets of Varian Biopharmaceuticals, Inc.	08/04
Windtree Therapeutics, Inc. announced that it expects to receive $1.5 million in funding	02/04
Windtree Therapeutics, Inc. Announces Resignation of John A. Tattory as Interim Chief Financial Officer and Principal Financial Officer	16/02
Windtree Therapeutics, Inc. Announces Resignation of John A. Tattory as Principal Financial Officer	16/02
Windtree Renews Agreement with Chang Gung University for Scientific Collaboration to Further SERCA2a Research	01/02
Windtree Therapeutics, Inc. Renews Agreement with Chang Gung University for Scientific Collaboration to Further SERCA2a Research	01/02
Windtree Therapeutics Engages Ladenburg to Evaluate Strategic Alternatives	31/01
Windtree Therapeutics Announces Engagement of Strategic Advisor to Support Assessment of Strategic Alternatives	31/01
Windtree Eliminates $15 Million Contingent Liability to Deerfield Management Company	25/01
WINDTREE THERAPEUTICS ANNOUNCES LICENSE AGREEMENT WITH LEE'S PHARMACEUTICALS TO DEVELOP AND COMMERCIALIZE ISTAROXIME, DUAL MECHANISM SERCA2A ACTIVATORS AND ROSTAFUROXIN FOR GREATER CHINA, ASIA PACIFIC REGION	18/01
Windtree Therapeutics Announces License Agreement with Lee’s Pharmaceuticals to Develop and Commercialize Istaroxime, Dual Mechanism SERCA2a Activators and Rostafuroxin for Greater China / Asia Pacific Region	17/01
Windtree Therapeutics, Inc. Enters into License, Development and Commercialization Agreement with Lee?s Pharmaceutical (HK) Ltd	17/01

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Windtree Therapeutics, Inc.

Azioni

WINT

US97382D5014

Altre lingue

Filtri